Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Cash Flow Reinvestment Rate
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Cash Flow Reinvestment Rate of 1.09x as of June 2023, reinvesting $44.49 Million (capex $31.00K plus investments $-44.46 Million) from operating cash flow of $40.67 Million. Explore Contineum Therapeutics, Inc. Class A Com (CTNM) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Reinvestment Rate (2023–2023)
Historical reinvestment intensity for Contineum Therapeutics, Inc. Class A Common Stock across 1 annual periods. Also explore CTNM total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Year-by-year capital reinvestment analysis for Contineum Therapeutics, Inc. Class A Common Stock. For live market cap and broader valuation context, see market cap of Contineum Therapeutics, Inc. Class A Com.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 3.41x | $65.98 Million | $19.35 Million | $414.00K | — |